All In Biotech

Drug Trial Radar · NCT05421663

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

A Phase 1b/2, Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants With B-cell Non-Hodgkin Lymphoma

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

166

Actual

Start

Aug 12, 2022

Primary completion

Jul 30, 2041

Study completion Jul 30, 2041

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jun 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1b/2, multicenter, open-label, study of JNJ-90014496, an autologous dual targeting chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD20 and CD19, for the treatment of adult participants with relapsed or refractory (r/r) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse large B-cell lymphoma (DLBCL).

Conditions

  • Lymphoma, Non-Hodgkin
  • Lymphoma, B-Cell
  • Lymphoma, Large B-Cell, Diffuse

Interventions

  • JNJ-90014496Biological

    JNJ-90014496, an autologous dual targeting chimeric antigen receptor (CAR) - T cell therapy targeting Cluster of differentiation (CD)20 and CD19.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b: Occurrence of Adverse Events (AEs) [Safety and Tolerability]Time frame: Up to 15 Years post JNJ-90014496 infusion
  2. Phase 2: Overall Response (OR) As Assessed by Independent Review Committee (IRC)Time frame: Up to 6 months post last participant's JNJ-90014496 infusion

Locations

32 sites in 8 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • University of Iowa Hospital and Clinics

    Iowa City, Iowa

  • University of Kentucky Medical Center

    Lexington, Kentucky

  • Rutgers Cancer Institute of New Jersey

    Piscataway, New Jersey

  • Levine Cancer Institute

    Charlotte, North Carolina

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Greco Hainesworth Tennessee Oncology Centers for Research

    Nashville, Tennessee

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • St. David's South Austin Medical Center

    Austin, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Texas Transplant Institute

    San Antonio, Texas

  • Swedish Cancer Institute

    Seattle, Washington

  • St Vincents Hospital Melbourne

    Fitzroy, Australia

  • The Alfred Hospital

    Melbourne, Australia

  • Fiona Stanley Hospital

    Murdoch, Australia

  • Calvary Mater Newcastle Hospital

    Waratah, Australia

  • Princess Margaret Cancer Centre University Health Network

    Toronto, Ontario, Canada

  • Rigshospitalet

    Copenhagen, Denmark

  • Odense University Hospital

    Odense, Denmark

  • Erasmus MC

    Rotterdam, Netherlands

  • UMC Utrecht

    Utrecht, Netherlands

  • Seoul National University Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Hosp Univ Vall D Hebron

    Barcelona, Spain

  • Hosp Clinic de Barcelona

    Barcelona, Spain

  • ICO L'Hospitalet - Hospital Duran i Reynals

    Barcelona, Spain

  • Hosp Univ Fund Jimenez Diaz

    Madrid, Spain

  • University College London Hospitals

    London, United Kingdom

  • The Christie NHS Foundation Trust Christie Hospital

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.